Skip to main content
VSQTF
OTC Life Sciences

Hydreight Q2 Revenue Soars 421% to $28M, Reaffirms $150M FY Guidance

Tom Rudovsky · Reported by PR Newswire
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.481
Mkt Cap
$50.147M
52W Low
$0.3
52W High
$0.723
52W Position info
60% above low
Off High info
33% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

VSQTF sits 60% above its 52-week low of $0.3 on light trading volume (0.2× avg).

Summary

Hydreight delivered record Q2 2026 results with revenue of $28.0 million, up 421% year-over-year and 12.5% sequentially. Net income reached $2.5 million and adjusted EBITDA $3.2 million, both sharply higher than the prior-year period. The company reaffirmed its fiscal 2026 revenue guidance of approximately $150 million, implying significant acceleration in the second half. Gross margin declined due to a higher mix of pharmacy sales, but the company maintains $20 million in cash and $35 million in working capital. The virtual healthcare/direct-to-consumer segment generated $22.8 million in Q2 revenue, up from $0.7 million a year ago, driven by the VSDHOne platform. Management will host an investor webcast on September 1, 2026, with a live analyst Q&A.

At the time of this announcement, VSQTF was trading at $0.48 on OTC in the Life Sciences sector, with a market capitalization of approximately $50.1M. The 52-week trading range was $0.30 to $0.72. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

VSQTF - Latest Insights

VSQTF
Jun 01, 2026, 9:32 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.5637
Real-time Price: $0.4023 info
Change: -$0.1614 (-29%) info
Market Cap: $41.951M info